North America

In North America, Stallergenes Greer continues to be a prominent player in the allergen immunotherapy (AIT) landscape, known for our strong market presence and unwavering support from our dedicated service teams. Despite economic headwinds faced in 2023, we remained resilient, safeguarding our core business while maintaining healthy profit margins. This resilience underscores the enduring value we continue to offer to our customers.

Establishment of a dedicated Food Allergy business unit

In a significant move during the fall of 2023, Stallergenes Greer acquired the rights to the peanut oral immunotherapy Palforzia®. Subsequently, our focus has been on establishing a specialised Food Allergy business unit. This endeavor involved building dedicated sales and commercial teams and working to fully transition the product into the AIT portfolio.

Investing in our core business

Recognising the escalating demand for allergen extracts, Stallergenes Greer has made strategic investments in enhancing manufacturing efficiencies. These efforts are particularly geared towards elevating production levels for pollens, our most sought-after extract category. Our California manufacturing plant, Allermed Laboratories, LLC plays a key role in this undertaking. By bolstering our inventory of key items, we aim to differentiate ourselves in the market, creating a distinctive identity that resonates with our target demographic and fosters brand loyalty.

Community engagement

In alignment with our commitment to advancing allergy care, Stallergenes Greer actively participated in and exhibited at prominent national allergy conferences, namely AAAAI in San Antonio, Texas, and ACAAI in Anaheim, California. These platforms provided invaluable opportunities to engage with allergy specialists, showcasing our comprehensive allergy portfolio.

Further, we demonstrated our commitment to nurturing future talent in the field of allergy by sponsoring 10 fellows-in-training (FITs) with scholarships to attend the ACAAI conference. This initiative not only supports the educational pursuits of emerging allergy specialists but also underscores our dedication to fostering leadership within the healthcare community.

As we navigate the dynamic landscape of AIT in North America, Stallergenes Greer remains steadfast in its mission to deliver innovative solutions and unparalleled support to our customers. Through strategic initiatives and community engagement efforts, we are poised to sustain our leadership position while driving positive impact in allergy care.

Sustained performance of veterinary business

The U.S. veterinary business, which celebrated its 40th anniversary of manufacturing, continues to provide veterinarians and pet owners with USDA licensed allergen extracts and AIT to help animals suffering from allergies. In 2023, we collaborated with real owners of pets who have been through the allergy journey and were interested in telling their stories—three dog owners and two cat owners passionately talk about their experiences with their pets’ allergies and how AIT has helped their pets live more comfortable lives. These dynamic and emotion-evoking videos will be shared on the Pets Get Allergies website as well as on our social media channels to educate pet owners about AIT and how it can help their pet get the relief they need from allergies.

Additionally, we sponsored a veterinary dermatologist who developed an accredited continuing education course for primary care veterinarians to help them learn more about how to confidently and accurately diagnose and treat pets with atopic dermatitis.

Canada: an expanding portfolio

In 2023, our Canadian operations continued to invest in quality and inventory management systems and build internal expertise to support future growth that keeps patients at the center.

A veterinary biologic import license was awarded to Stallergenes Greer Canada during the year and the affiliate is now also serving veterinary dermatologist customers with bulk allergenic extracts.

Support for allergy research continued in 2023 with sponsorship of the Canadian Asthma, Allergy and Immunology Foundation (CAAIF) and the Food Allergy Immunotherapy Program (FAIT) at BC Children’s Hospital (Vancouver, British Columbia).

As a veterinary dermatologist, I receive questions every single day from primary care veterinarians who are curious about allergen testing and allergen immunotherapy. Sadly, there is so much confusion, and so many misconceptions, out there about these important topics – amongst both veterinary teams and pet owners. These often result in under-utilisation, inappropriate utilisation, and/or suboptimal outcomes with allergen testing and immunotherapy. I created this course to help clear up the confusion and misconceptions to help everybody better understand how, when, and with which patients to utilise allergen testing and allergen immunotherapy.”

DR. MEAGAN PAINTER